Wolfe Research analyst Kalpit Patel upgraded Corcept Therapeutics (CORT) to Peer Perform from Underperform with no price target after the company received approval for relacorilant with nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer about 2.5 months ahead of its PDUFA deadline. While the firm continues to question the sustainability of the core Cushing’s franchise, it sees the ovarian cancer approval removing “a key downside scenario for the stock,” the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CORT:
- Corcept Therapeutics price target raised to $110 from $100 at Canaccord
- Corcept Faces Investor Suit Over Relacorilant NDA Disclosure
- Corcept Wins FDA Approval for Lifyorli Ovarian Cancer Therapy
- Corcept confirms FDA approves Lifyorli for platinum-resistant ovarian cancer
- Corcept Rockets 48% after FDA Lifyorli Approval — What Does This Mean for CORT Stock?